RIMINI, MARGHERITA
 Distribuzione geografica
Continente #
NA - Nord America 86
EU - Europa 59
AS - Asia 30
OC - Oceania 4
Totale 179
Nazione #
US - Stati Uniti d'America 84
RU - Federazione Russa 23
CN - Cina 16
SE - Svezia 11
IT - Italia 9
SG - Singapore 8
DE - Germania 6
AU - Australia 4
FI - Finlandia 3
FR - Francia 3
IN - India 3
ES - Italia 2
IE - Irlanda 2
PH - Filippine 2
CA - Canada 1
IR - Iran 1
MX - Messico 1
Totale 179
Città #
Boardman 20
New York 18
Ashburn 16
Shanghai 11
Moscow 9
Brisbane 4
Rome 4
Singapore 4
Helsinki 3
Lawrence 3
Princeton 3
Washington 3
Dublin 2
Los Angeles 2
Lucca 2
Lyon 2
Manila 2
Seattle 2
Valencia 2
Visakhapatnam 2
Yekaterinburg 2
Borås 1
Hamm 1
Mexico City 1
Milan 1
Nizhniy Novgorod 1
Nuremberg 1
Omsk 1
Pisa 1
Pune 1
Santa Clara 1
St Petersburg 1
Winnipeg 1
Totale 128
Nome #
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 16
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 14
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 14
Cholangiocarcinoma: new perspectives for new horizons 14
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 13
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis 12
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 12
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 12
Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma 11
Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index 11
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? 10
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 10
Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population Study 10
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study 9
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study 8
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 8
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 8
The oncologic burden of residual disease in incidental gallbladder cancer: An elastic net regression model to profile high-risk features 7
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 7
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 6
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma 5
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 5
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 2
Combined hepatocellular-cholangiocarcinoma: morpho-molecular updates and considerations 1
Totale 225
Categoria #
all - tutte 2.574
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.574


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 2 0 0 0 0 0 0
2021/20222 0 0 0 1 0 0 0 0 0 0 0 1
2022/202331 9 2 0 0 1 7 3 2 2 2 0 3
2023/2024161 12 1 18 13 8 25 3 10 0 5 22 44
2024/202529 29 0 0 0 0 0 0 0 0 0 0 0
Totale 225